Patent
Polysaccharide exotoxoid conjugate vaccines
Reads0
Chats0
TLDR
A water-soluble covalent polysaccharide-antigen conjugate with a molecular size between 140,000 and 4,500,000 dalton and a nominal poly-saccharides/protein ratio between 0.25 and 2, capable of producing T-cell dependent antibody response to poly-sarccharide from a number of pathogenic bacterial organisms is prepared by mixing Tcell dependent antigen with an electrophilically activated poly-Sarcide hapten which poly-charide had previously been heat sized until more than 60% attainedAbstract:
A water-soluble covalent polysaccharide-antigen conjugate having a molecular size between 140,000 and 4,500,000 dalton and a nominal polysaccharide/protein ratio between 0.25 and 2, capable of producing T-cell dependent antibody response to polysaccharide from a number of pathogenic bacterial organisms is prepared by mixing T-cell dependent antigen with an electrophilically activated polysaccharide hapten which polysaccharide had previously been heat sized until more than 60% attained a molecular size between 200,000 and 2,000,000 dalton.read more
Citations
More filters
Patent
Oligosaccharide conjugate vaccines
TL;DR: In this paper, an improved method for producing oligosaccharide conjugate vaccines was proposed, which elicited a monospecific and homogeneous immune response to capsular polysaccharide.
Patent
Glycoproteinic conjugates having trivalent immunogenic activity
Massimo Porro,Paolo Costantino +1 more
TL;DR: Glycoproteinic conjugates having trivalent immunogenic activity obtained by binding, by a covalent bond, to a protein selected among CRM 197, tetanus toxoid, and pertussis toxin, wherein said oligosaccharidic haptens are previously activated by introducing terminal esters as mentioned in this paper.
Patent
Dual carrier immunogenic construct
James J. Mond,Andrew Lees +1 more
TL;DR: A dual carrier immunogenic construct as mentioned in this paper is composed of at least one primary carrier comprising large molecular weight molecule of greater than a 70 KD molecular weight and at least a secondary carrier comprising a T-dependent antigen conjugated to a primary carrier.
Patent
Pneumococcal polysaccharide conjugate vaccine
Peter J. Kniskern,Charlotte C. Yu Ip,Arpi Hagopian,Jr. John P. Hennessey,William J. Miller,Dennis J. Kubek,Pamela D Burke,Stephen Marburg,Richard L. Tolman +8 more
TL;DR: In this paper, a pneumococcal conjugate vaccine comprising partially hydrolyzed, highly purified, capsular polysaccharide (Ps) from Streptococcus pneumoniae bacteria (pneumococci, Pn) linked to an immunogenic carrier protein, is produced by a new process.
PatentDOI
Group B streptococcus type II polysaccharide-tetanus toxoid conjugate vaccines
TL;DR: The coupling strategy which selectively modified a portion of the sialic acid residues of types II polysaccharide before coupling the polysacchide to TT preserved the epitope essential to protective immunity and enhanced the immunogenicity of the poly Saccharide.
References
More filters
Patent
Immunogenic polysaccharide-protein conjugates
TL;DR: In this paper, the authors modified polysaccharides to generate a terminally-located aldehyde group by controlled oxidation of vicinal hydroxyl groups, e.g. of unlinked terminal non-reducing sialic acid residues.